Department of Radiation Oncology, Chi Mei Medical Center, Tainan, Taiwan.
Center of General Education, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.
Medicine (Baltimore). 2024 Jun 7;103(23):e38427. doi: 10.1097/MD.0000000000038427.
It is difficult to reirradiate head and neck cancers because of the toxicity from previous radiation dose delivery. Conventional volumetric modulated arc therapy (VMAT) and intensity-modulated radiation therapy often have poor target coverage. The new HyperArcTM VMAT (HA-VMAT) planning approach reportedly has better target coverage, higher conformity, and can spare normal organs compared to conventional VMAT; however, research on recurrent head and neck cancers is limited. Here, we report the clinical outcomes of HA-VMAT for previously irradiated hypopharyngeal cancer with solitary recurrence in the first cervical vertebra (C1).
A 52-year-old Asian male was diagnosed with a hypopharyngeal cancer. The patient received concurrent chemoradiotherapy with a radiation dose of 70 Gy in 33 fractions and achieved complete clinical response. Two years later, solitary recurrence was observed in the C1 vertebra.
Solitary recurrence in the C1 vertebra.
Owing to concerns regarding the toxicity to adjacent organs, we decided to use HA-VMAT to achieve better tumor coverage and critical organ sparing.
Tumor regression was observed on the imaging. At 9 months follow-up, the patient was disease-free and had no late toxicities.
This is the first report regarding the clinical outcomes of HA-VMAT for previously irradiated hypopharyngeal cancer with solitary recurrence over the C1 vertebra. HA-VMAT achieves highly conformal dose distribution and excellent sparing of critical organs. There was a favorable initial clinical response with no toxicity. Long-term follow-up is essential in such cases.
由于先前放射剂量的毒性,头颈部癌症的再放疗较为困难。传统的容积旋转调强放疗(VMAT)和调强放疗通常靶区覆盖不佳。新的 HyperArcTM VMAT(HA-VMAT)计划方法据报道具有更好的靶区覆盖、更高的适形性,并能与传统 VMAT 相比保护正常器官;然而,针对复发性头颈部癌症的研究有限。在此,我们报告先前接受过放射治疗的单一复发性下咽癌在第一颈椎(C1)的 HA-VMAT 临床结果。
一名 52 岁的亚洲男性被诊断患有下咽癌。患者接受了同期放化疗,放射剂量为 70Gy,共 33 次,达到完全临床缓解。两年后,C1 椎体发现单发复发。
C1 椎体单发复发。
由于担心对相邻器官的毒性,我们决定使用 HA-VMAT 来实现更好的肿瘤覆盖和关键器官保护。
影像学上观察到肿瘤消退。随访 9 个月时,患者无疾病且无迟发性毒性。
这是首例关于 HA-VMAT 治疗先前接受过放射治疗的单一复发性 C1 椎体下咽癌的临床结果的报告。HA-VMAT 实现了高度适形的剂量分布和对关键器官的极好保护。初始临床反应良好,无毒性。在这种情况下,长期随访至关重要。